RGEN - Repligen Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
97.25
+0.75 (+0.78%)
As of 11:11AM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close96.50
Open97.46
Bid97.52 x 900
Ask97.91 x 1100
Day's Range95.50 - 99.02
52 Week Range52.87 - 109.94
Volume73,349
Avg. Volume541,180
Market Cap5.065B
Beta (5Y Monthly)0.98
PE Ratio (TTM)221.02
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Repligen Appoints Rohin Mhatre, Ph.D. to Board of Directors

    Repligen Corporation (RGEN) today announced the appointment of life sciences industry executive Rohin Mhatre, Ph.D., to its Board of Directors. Dr. Mhatre brings to the director role over 25 years of relevant experience, which includes his current position as Senior Vice President, Product and Technology Development for Biogen Inc., a leading multinational biopharmaceutical company. Dr. Mhatre leads a cross-functional department responsible for product and process development, process analytics and small-scale manufacturing.

  • GlobeNewswire

    Repligen Reports Fourth Quarter and Full Year 2019 Financial Results

    Reports quarterly revenue of $69.5 million, representing 34% year-over-year growth, and annual revenue of $270.2 million represents 39% year-over-year growthOverall organic.

  • GlobeNewswire

    Repligen to Report Fourth Quarter and Full Year 2019 Financial Results

    Repligen Corporation (RGEN) today announced that the Company will report its fourth quarter and full year 2019 financial results on Thursday, February 20, 2020. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the three- and twelve-month reporting periods ended December 31, 2019. The conference call will be accessible by dialing toll-free (844) 701-1063 for domestic callers and (412) 317-5487 for international callers.

  • GlobeNewswire

    Repligen to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Company will present at the 38th annual J.P. Morgan Healthcare Conference, to be held at the Westin St. Francis in San Francisco. Tony J. Hunt, Repligen’s president and chief executive officer, is scheduled to present a company overview on Wednesday, January 15, 2020 at 11:30 a.m. PT. A live audio webcast of the presentation will be accessible through the Investor Events section of the Company’s website at www.repligen.com.

  • GlobeNewswire

    Repligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance

    Reports quarterly revenue of $69.4 million, representing 40% reported growth and 28% organic growth year-over-yearRaises revenue guidance to $267-$270 million for full year.

  • GlobeNewswire

    Repligen to Report Third Quarter 2019 Financial Results

    Repligen Corporation (RGEN) today announced that the Company will report its third quarter 2019 financial results on Thursday, October 31, 2019. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- and nine-month reporting periods ended September 30, 2019. The conference call will be accessible by dialing toll-free (844) 701-1063 for domestic callers and (412) 317-5487 for international callers.

  • CNW Group

    Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes

    TORONTO and HOUSTON , Sept. 24, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced the appointment of Ms. Karen Dawes to the Board of Directors of Medicenna and the voting results from the Company's annual meeting of shareholders held today, September 24, 2019 in Toronto (the "Meeting"). A total of 36.15% of the issued and outstanding common shares of the Company were represented in person and by proxy at the Meeting.

  • PR Newswire

    S&P Dow Jones Indices Announces Nine Companies Set to Join S&P MidCap 400; Ten Companies to Join S&P SmallCap 600

    NEW YORK , Sept. 6, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following index adjustments to the S&P MidCap 400 and S&P SmallCap 600 to ensure each index more appropriately represents its ...

  • GlobeNewswire

    Repligen Reports Second Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance

    Reports record quarterly revenue of $70.7 million, representing 48% year-over-year growth and 46% organic growthRaises revenue guidance to $264-$268 million for full year 2019,.

  • GlobeNewswire

    Repligen to Report Second Quarter 2019 Financial Results

    Repligen Corporation (RGEN) today announced that the Company will report its second quarter 2019 financial results on Thursday, August 1, 2019. The conference call will be accessible by dialing toll-free (844) 701-1063 for domestic callers and (412) 317-5487 for international callers. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website.

  • GlobeNewswire

    Repligen Corporation Announces Closing of Public Offerings of $138.1 Million of Common Stock and $287.5 Million of 0.375% Convertible Senior Notes due 2024, Including Full Exercise of Underwriters’ Options

    Repligen Corporation (RGEN) (“Repligen”) today announced the closing of its previously announced concurrent underwritten public offerings of an aggregate of 1,587,000 shares of its common stock (the “Shares”) at a public offering price of $87.00 per share for gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, of approximately $138.1 million, and $287.5 million aggregate principal amount of 0.375% Convertible Senior Notes due 2024 (the “Notes”), which includes the exercise in full of the underwriters’ option to purchase 207,000 additional Shares and $37.5 million additional Notes. The offering of the Shares (the “Shares Offering”) is expected to result in approximately $130.7 million in net proceeds to Repligen after deducting underwriting discounts and commissions and other estimated offering expenses payable by Repligen.

  • GlobeNewswire

    Repligen Corporation Announces Pricing of Public Offerings of $120 million of Common Stock and $250 million of 0.375% Convertible Senior Notes due 2024

    Repligen Corporation (RGEN) (“Repligen”) today announced the pricing of concurrent underwritten public offerings of 1,380,000 shares of its common stock (the “Shares”) at a public offering price of $87.00 per share for gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, of approximately $120 million, and $250 million aggregate principal amount of 0.375% Convertible Senior Notes due 2024 (the “Notes”). In addition, Repligen has granted the underwriters of the offering of Shares (the “Shares Offering”) a 30-day option to purchase up to an additional 207,000 Shares and the underwriters of the offering of Notes (the “Notes Offering”) a 13-day option to purchase up to $37.5 million aggregate principal amount of additional Notes solely to cover over-allotments.

  • GlobeNewswire

    Repligen Corporation Announces Proposed Public Offerings of $100 million of Common Stock and $250 million of Convertible Senior Notes

    Repligen Corporation (RGEN) (“Repligen”) today announced that it has commenced concurrent underwritten public offerings of $100,000,000 in shares of its common stock (the “Shares”) and $250,000,000 aggregate principal amount of convertible senior notes due 2024 (the “Notes”). In addition, Repligen expects to grant the underwriters of the offering of Shares (the “Shares Offering”) a 30-day option to purchase up to $15,000,000 of additional Shares and the underwriters of the offering of Notes (the “Notes Offering”) a 13-day option to purchase up to $37,500,000 aggregate principal amount of additional Notes solely to cover over-allotments. The Notes will be senior, unsecured obligations of Repligen, and interest will be payable semi-annually in arrears.

  • GlobeNewswire

    Repligen to Present at Jefferies 2019 Healthcare Conference

    WALTHAM, Mass., June 04, 2019 -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that Jon K..

  • GlobeNewswire

    Repligen Reports First Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance

    Reports first quarter revenue of $60.6 million, representing 35% year-over-year growth and 37% organic growthRaises revenue guidance to $235-$241 million for full year 2019,.

  • ACCESSWIRE

    Repligen Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 9, 2019 / Repligen Corp. (NASDAQ: RGEN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 9, 2019 at 8:30 AM Eastern Time. ...

  • GlobeNewswire

    Repligen to Report First Quarter 2019 Financial Results

    WALTHAM, Mass., May 02, 2019 -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2019 financial results on Thursday, May 9,.

  • GlobeNewswire

    Repligen Corporation Prices Public Offering of Shares of Common Stock

    Repligen Corporation (RGEN) today announced the pricing of an underwritten public offering of 2,734,375 shares of its common stock at a public offering price of $64.00 per share. In addition, Repligen Corporation has granted the underwriters a 30-day option to purchase up to an additional 410,156 shares of its common stock at the public offering price, less underwriting discounts and commissions. Repligen expects proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares.

  • GlobeNewswire

    Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock

    Repligen Corporation (RGEN) today announced that it has commenced an underwritten public offering of $175,000,000 in shares of its common stock. In addition, Repligen Corporation expects to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 in shares of its common stock in connection with the proposed public offering. All shares of common stock will be offered by Repligen Corporation.

  • GlobeNewswire

    Repligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies and Reports Preliminary First Quarter 2019 Financial Results

    Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held C Technologies, Inc. for approximately $240 million, comprised of $192 million in cash plus $48 million in Repligen common stock.